Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 13, 2026
- $1.95B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $595.8K in total
- 1
- 13F holdersQ2 2026, +22 vs. previous quarter
- 218
- 13F valueReported value at the end of Q2 2026
- $2.76B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$42.8M
- No comparable prior period
- Free cash flow, FY2025
- -$42.1M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 16.9M
- Shares sold short
- Change
- +848.8K
- +5.3% vs. previous
- Days to cover
- 10.13
- At average daily volume
Superinvestors holding TRVI, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Trevi Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Trevi Therapeutics, Inc.'s share of the portfolio
- Shares
- 1,544,644
- Value
- $28.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Trevi Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:55 PM ET | Sep 15 | 2 days | Heffernan Michael ThomasDirector | SSale | −39.5K | $15.09 | −$595.8K | −86.1%6.35K after | 4 lots10b5-1 |
| Mar 26, 2025 (view filing) | Mar 25 | 1 day | Sciascia ThomasChief Scientific Officer | SSale | −2.63K | $6.60 | −$17.4K | −1.2%221.4K after | |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Good Jennifer LPresident & CEO | SSale | −5.26K | $6.58 | −$34.6K | −2.4%213.3K after | |
| Mar 12, 2025 (view filing) | Mar 10 | 2 days | Simon FarrellChief Commercial Officer | SSale | −81.3K | $6.75 | −$549.1K | −51.4%76.9K after | 2 lots10b5-1 |
| Sep 9, 2024 (view filing) | Sep 6-9 | 3 days | Good Jennifer LPresident & CEO | SSale | −6.06K | $3.03 | −$18.4K | −2.8%213.3K after | 2 lots |
| Sep 5, 2024 (view filing) | Sep 3-5 | 2 days | Good Jennifer LPresident & CEO | SSale | −55.1K | $3.09 | −$170.1K | −20.5%213.3K after | 3 lots |
| Aug 29, 2024 (view filing) | Aug 27 | 2 days | Meeker David PDirector | SSale | −4.55K | $2.93 | −$13.3K | −1.3%352.5K after | |
| Aug 21, 2024 (view filing) | Aug 19 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −16.5K | $2.96 | −$48.8K | −7.0%220.3K after | |
| Aug 16, 2024 (view filing) | Aug 14-16 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −31.5K | $2.77 | −$87.3K | −12.5%220.3K after | 3 lots |
| May 31, 2024 (view filing) | May 29 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −53.4K | $2.55 | −$136.1K | −19.9%214.4K after |
Top 10 13F holders, Q2 2026
See all 218 holdersThe largest institutional positions in Trevi Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 13,222,228 | $246.6M | 15.53% | 00.0% | Unchanged |
| FMR LLC | 12,562,839 | $234.3M | 0.01% | +4,524,778+56.3% | Added |
| BlackRock, Inc. | 11,155,026 | $208.0M | 0.00% | +914,840+8.9% | Added |
| Frazier Life Sciences Management, L.P. | 9,939,447 | $185.4M | 4.04% | −1000.0% | Reduced |
| Wellington Management Group LLP | 5,684,592 | $106.0M | 0.02% | +495,504+9.5% | Added |
| Vanguard Capital Management LLC | 5,530,675 | $103.1M | 0.00% | +552,108+11.1% | Added |
| Vivo Capital, LLC | 5,094,668 | $95.0M | 8.68% | 00.0% | Unchanged |
| Woodline Partners LP | 4,081,333 | $76.1M | 0.24% | +3,080,551+307.8% | Added |
| Vestal Point Capital, LP | 3,100,000 | $57.8M | 1.35% | +933,496+43.1% | Added |
| MPM Oncology Impact Management LP | 3,073,577 | $57.3M | 3.50% | −224,853−6.8% | Reduced |
Holders of 5% or more of TRVI
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Trevi Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 13D/A | 10.50%15.1M shares | −1.10 ppfrom 11.60% | Nov 2, 20218 filings | May 7, 2026 | SEC |
| FMR LLC | 13G/A | 8.80%12.6M shares | +2.50 ppfrom 6.30% | Feb 5, 20263 filings | Aug 6, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 7.00%8.51M shares | −3.60 ppfrom 10.60% | Apr 18, 20226 filings | Nov 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 6.90%9.78M shares | +1.30 ppfrom 5.60% | Oct 17, 20252 filings | Oct 27, 2026 | SEC |